Staff Software Engineer

Hippocratic AI launches two industry firsts: AI Front Door and Nurse Co-Pilot to expand clinical care and access. PR Newswire Today at 11:30am PDT PR Newswire PALO ALTO, Calif., Apr. 16, 2026 The first safe, omni-topic Voice AI for patient access, including inbound calls and the first AI voice assistant built for inpatient nurses - giving healthcare leaders the tools to move from scarcity to abundance PALO ALTO, Calif., Apr. 16, 2026 /PRNewswire/ - Hippocratic AI today announced two new Voice AI products that mark a turning point in how healthcare organizations deliver care: AI Front Door, a safe, always-available AI health agent that replaces fragmented call centers and digital front doors with a single, continuous patient relationship over multiple calls, delivering omni-topic care across all patient needs; and Nurse Co-Pilot, the first AI voice assistant built specifically for inpatient nurses, co-developed with Cincinnati Children's Hospital Medical Center, OhioHealth, and Cleveland Clinic, designed to return 1-4 hours of nursing per shift. Both products are powered by Hippocratic AI's patented Polaris safety architecture - with 180+ million patient interactions, 99.90% correct clinical advice, 0.00% severe harm events, and validation from 7,500+ U.S.-licensed clinicians. "For all of healthcare's history, care has been designed around the assumption of scarcity," said Munjal Shah, CEO and co-founder of Hippocratic AI. "AI Front Door and Nurse Co-Pilot change that equation. One gives every patient a personal health agent. The other gives every nurse an AI assistant. Together, they put healthcare leaders in control of a shift from scarcity to abundance." AI FRONT DOOR: ONE AGENT. EVERY NEED. EVERY CHANNEL. The "digital front door" promised access but delivered phone trees, long hold times, and disconnected experiences. AI Front Door replaces this with a single intelligent agent that resolves needs in one continuous conversation instead of deflecting them. Omni-topic. A patient can schedule an appointment, ask about lab results, address a billing issue, and follow up on care instructions, all in one conversation, no transfers, no restarts. Relationship-based. Every interaction builds on the last. The AI remembers patient history, preferences, and prior conversations, shifting the experience from transactional to longitudinal. Less call center, more care. Patient advocate. AI Front Door prepares patients before visits, follows up afterward, and closes care gaps in between - serving as a continuous member advocate, guiding members through benefits, preparing them for appointments, and keeping care plans on track. Operates externally - It doesn't stop at answering questions. The AI coordinates referrals, arranges transportation, contacts employers, and manages the logistics that typically fall through the cracks. Omnichannel. Start on the phone, continue over text, finish in the app - one seamless conversation that never loses context. Caregiver in the loop. Whether a patient has a caregiver or is one, AI Front Door keeps everyone connected - authorizations, status updates, and care discussions, all coordinated. "Every time a patient calls, that's a window of engagement, even if the initial call is just to reset a password. Most systems squander it - transfers, hold times, callbacks. AI Front Door doesn't. It resolves the need right there, powered by 31 coordinated LLM models that can safely navigate any topic, from scheduling to clinical needs in a single conversation." - Vishal Parikh, Chief Product Officer, Hippocratic AI. AI Front Door is already being deployed with initial partners, including Wellspan and Cincinnati Children's with more healthcare leaders coming on board this month. NURSE CO-PILOT: THE FIRST AI BUILT FOR BEDSIDE NURSES, BY NURSES While most healthcare AI has focused on physician documentation and administrative workflows, nurses, the largest segment of the clinical workforce, have seen little of that investment. Nurse Co-Pilot is designed to take work away from nurses, not pile more on. Co-developed with nursing leaders at Cincinnati Children's, OhioHealth, and Cleveland Clinic, it launches with four critical inpatient workflows: Admission Education - Walks newly admitted patients through what to expect, giving nurses time back for hands-on care. Patient Education - Delivers consistent education throughout the stay, from disease management to discharge preparation. Caregiver Engagement - Prepares family members for life after discharge: medications, warning signs, follow-ups, daily routines. The education that prevents readmissions. Medication Adherence - Walks patients through every medication so they leave informed and adherent. Each workflow, if executed by a nurse, will take from 10-15 minutes. By deploying Nurse Co-Pilot, the result can be 1-4 hours returned per nurse, per shift, depending on usage back to direct patient care. How it works: A nurse launches Nurse Co-Pilot directly from the EHR, selects the patient and workflow, and the AI calls the patient by phone - no app download required. After the call, a structured clinical summary and full transcript are written back to the EHR automatically. The nurse triggers every call, reviews every result, and maintains full clinical oversight. The AI is the tool; the nurse is the clinician. "There's never been enough time in a shift to reach every patient the way you want to," said Amy McCarthy, Chief Nursing Officer, Hippocratic AI. "Nurse Co-Pilot gives nurses an AI assistant that ensures every patient gets the follow-up they need, while giving nurses time back for hands-on care." ABOUT HIPPOCRATIC AI Hippocratic AI is building the safety layer for healthcare AI. The company's patented Polaris safety architecture ensures that AI agents in healthcare meet the highest standards of clinical safety, validated by licensed healthcare professionals. Founded by Munjal Shah, the company is headquartered in Palo Alto, California. For more information, visit hippocraticai.com. SOURCE Hippocratic AI This is a paid placement. For further inquiries, please contact PR Newswire directly.

Hippocratic AI consolidates Life Sciences leadership with acquisition of Grove AI and key executive appointments. The move establishes a dedicated Life Sciences Division and senior executive advisory council to accelerate generative AI across the biopharma and medtech value chain. PALO ALTO, Calif. - (BUSINESS WIRE) - #GenAI - Hippocratic AI, the global leader and pioneer in patient-facing generative AI healthcare agents, today announced a major expansion of its life sciences business. The company has acquired Grove AI, appointed a President of Life Sciences, launched a world-class Life Sciences Executive Advisory Council, and entered into a strategic collaboration with Boston Consulting Group (BCG). Together, these milestones establish Hippocratic AI as the category leader in deploying safe, scalable, and clinically grounded generative AI across the biopharma and medtech value chain, from R&D and clinical trials to commercialization and post-market patient engagement. "Real impact in the life sciences sector requires deeply specialized models, exhaustive safety testing, and LLM safety architectures built to operate within highly regulated environments," said Munjal Shah, Co-founder and CEO of Hippocratic AI. "That is why Hippocratic AI has strategically expanded its life sciences leadership - acquiring Grove AI, appointing a dedicated President of Life Sciences, convening a world-class Executive Advisory Council, and partnering with Boston Consulting Group." Hippocratic AI's generative AI agents are powered by its proprietary Polaris safety architecture, delivering high-fidelity clinical reasoning and enterprise-grade auditability at scale. Backed by more than 150 million clinical interactions to date and following its recent $126M Series C financing, with a portion of proceeds earmarked for M&A, the company is continuing to scale production-ready generative AI agents that life sciences organizations can trust across research, clinical, and patient engagement workflows. Acquisition of Grove AI to Accelerate Clinical Engagement Capabilities Hippocratic AI has acquired Grove AI, a leader in agentic AI for pharma R&D and clinical trial operations, uniting two teams aligned around a shared vision of healthcare abundance, expanding access, accelerating research, and removing friction across the life sciences ecosystem. Grove AI's team and technology now form a core pillar of Hippocratic AI's Life Sciences Division. Over the past year, Grove AI's platform supported more than 10 million patient interactions, uncovering opportunities to automate and transform thousands of slow, manual workflows across clinical research and development. "At Grove AI, we built the leading agentic AI solution for pharma R&D by working directly with clinical teams and patients at scale," said Tran Le, Co-Founder of Grove AI. "By joining Hippocratic AI, we can build on that foundation and accelerate the delivery of these capabilities to a much broader set of life sciences organizations, combining our innovation with Hippocratic AI's enterprise scale." The acquisition brings two cornerstone offerings to Hippocratic AI's life sciences portfolio: * AI Agent ("Grace"): an always-on, multilingual AI agent that supports end-to-end patient engagement, recruitment, and follow-up across voice, text, and email. * Grove AI PRM(TM)(Participant Relationship Management): a purpose-built platform that orchestrates AI-driven participant interactions with full transparency, human oversight, and regulatory alignment. "With our combined expertise, Hippocratic AI and Grove AI are uniquely positioned to lead the agentic AI transformation at a critical inflection point for the life sciences industry," said Sohit Gatiganti, Co-Founder of Grove AI. Today, the combined team is actively collaborating with five of the world's leading global pharmaceutical companies to deploy AI agents for patient and provider engagement at enterprise scale. Launch of Life Sciences Executive Advisory Panel To guide product development and ensure real-world relevance, Hippocratic AI has convened a Life Sciences Executive Advisory Panel, featuring seasoned leaders from the world's most respected pharmaceutical and medical device companies: * Jim Meyers, former Chief Commercial Officer at Gilead Sciences, who led the launch of 24 products, including 11 blockbuster brands. * Michael Norton, former VP of Global Medical Affairs at AbbVie, with over 20 years in R&D and medical leadership across AbbVie and Abbott. * David Pierce, former President of MedSurg, Endoscopy, and Urology at Boston Scientific, where he helped grow the company to over $20B in revenue. * Richard Klausner, former Director of the National Cancer Institute, former Executive Director at the Gates Foundation, and Co-founder of Altos Labs, a leading biotechnology company with more than $3 billion in funding, as well as Lyell Immunopharma, Juno Therapeutics, and Grail. This executive advisory panel brings deep expertise across therapeutic areas, commercialization, medical affairs, quality, and device innovation, ensuring Hippocratic AI's offerings are tuned to the evolving needs of life sciences partners. "I decided to join Hippocratic AI as an advisor due to the team's commitment to innovation that puts the patient and patient safety first. Their proven track record of supporting millions of patient clinical calls, powered by the Polaris Constellation Architecture, uniquely positions them to continue to drive meaningful change across life sciences. I am excited to apply my extensive industry experience during this pivotal period to help deepen the company's vertical expertise and navigate this complex landscape," said Jim Meyers, former Chief Commercial Officer at Gilead Sciences. Newly Appointed President of Life Sciences Leading the Life Sciences Division is Dr. Ahad Wahid, M.D., President of Life Sciences at Hippocratic AI. A former NHS surgeon and member of the UK General Medical Council's Quality Assurance Board, Dr. Wahid brings deep expertise in patient safety and regulatory rigor. He later spent a decade as a Partner at Boston Consulting Group, where he led global AI and healthcare transformation initiatives and advised executive teams and boards at more than 30 of the world's leading healthcare organizations. At Hippocratic AI, Dr. Wahid applies this combined clinical and strategic perspective to ensure AI adoption enhances care delivery while meeting the highest safety standards. "Hippocratic AI is building what life sciences has been waiting for: generative AI that can scale globally without compromising safety or regulatory integrity. The acquisition of Grove AI, combined with our expanded leadership team, advisory council, and collaboration with BCG, gives us the foundation to further operationalize agentic AI across research, clinical, and patient engagement workflows. My focus is ensuring these technologies are deployed responsibly, measurably, and at enterprise scale so innovation translates into real outcomes for patients and organizations alike," said Dr. Ahad Wahid, M.D., President of Life Sciences at Hippocratic AI. Strategic Collaboration with Boston Consulting Group As previously announced last week, Hippocratic AI has entered into a strategic collaboration with Boston Consulting Group (BCG) and BCG X to help pharma and medtech clients adopt generative AI solutions aligned with commercial, R&D, and medical affairs goals. Life sciences requires a strategic roadmap and deep understanding of regulatory requirements. BCG and Hippocratic AI will collaborate to bring integrated AI strategies, implementation services, and measurable ROI to the life sciences sector. This collaboration builds on BCG's AI transformation leadership and Hippocratic AI's pioneering generative AI healthcare agents, which are designed for safety, patient trust, and scale. "This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI's sophisticated AI agent platform, BCG's strategy and governance expertise, and BCG X's Health Care Commercial AI solution to help clients turn potential into measurable business value," said Ashkan Afhkami, BCG managing director and senior partner and global leader for the Health Care practice at BCG X. About Hippocratic AI Hippocratic AI has developed the safest generative AI Agents for healthcare. The company believes that generative AI has the ability to bring healthcare abundance to every person in the world. The company focuses on building non-diagnostic patient-facing clinical AI agents and does not allow its agents to be used to prescribe or diagnose. Hippocratic AI has received a total of $404 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA's NVentures, Premji Invest, SV Angel, Google's CapitalG, and numerous health systems. Learn more at https://hippocraticai.com/.